✦ LIBER ✦

l-Dopa induces under-damped visually guided motor responses in Parkinson’s disease

✍ Scribed by Wing-Lok Au; Ni Lei; Meeko M. K. Oishi; Martin J. McKeown

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 290 KB
Volume: 202
Category: Article
ISSN: 0014-4819
DOI: 10.1007/s00221-010-2156-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Beneficial effects of amantadine on L-do

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

✍ E. Luginger; G. K. Wenning; S. Bösch; W. Poewe 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Salsolinol, catecholamine metabolites, a

Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease

✍ A. Moser; F. Siebecker; P. Vieregge; P. Jaskowski; D. Kömpf 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 808 KB

Single-dose L-dopa response in early par

Single-dose L-dopa response in early parkinson's disease: Measurements with optoelectronic recording technique

✍ Dr. Bo Johnels; Páll E. Ingvarsson; Björn Holmberg; Michael Matousek; Göran Steg 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

## Abstract Twenty‐five patients with suspected Parkinson's disease were submitted to optoelectronic movement analysis with the Posturo‐ Locomotor‐Manual (PLM) test before and 60 min after a single dose of L‐Dopa. They were then examined clinically for diagnosis. Two patients were excluded due to L

Possible role for chlorpheniramine in th

Possible role for chlorpheniramine in the treatment of l-DOPA induced dyskinesia in Parkinson’s disease

✍ Karamanakos, Petros N. ;Pappas, Periklis ;Marselos, Marios 📂 Article 📅 2007 🏛 Springer 🌐 Dutch ⚖ 107 KB

The effects of cisapride on plasma L-dop

The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease

✍ Walter Diaz Neira; Vicenta Sanchez; Maria Angeles Mena; Dr. Justo Garcia de Yebe 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

Cisapride (CIS) is a prokinetic agent that increases gastrointestinal motility in normal individuals and improves constipation in Parkinson's disease (PD). We studied the effects of CIS on the clinical response and the peripheral pharmacokinetics of orally administered L-dopa given to patients with

Idazoxan, an alpha-2 antagonist, and L-D

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc